Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma: A single-institutional study with a long-term follow-up

T. Ohnoshi, K. Hayashi, K. Ueno, A. Tada, J. Mizuta, S. Tagawa, S. Matsutomo, Shinya Saito, K. Kawashima, Tadashi Yoshino, I. Kimura

Research output: Contribution to journalArticle

Abstract

Diffuse large-cell lymphoma (DLCL) is a neoplasm that is curable with chemotherapy in an appreciable percentage of patients. However, not all patients are cured and the best drug combination and optimal dose intensity have not yet been established. In an attempt to improve complete response rate and survival with minimal toxicity, we devised an alternating combination chemotherapy consisting of CHOP-Bleo (cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin) and POEM-Bleo (prednisolone, vincristine, etoposide, mitoxantrone, and bleomycin). Between March 1986 and October 1990, 30 newly-diagnosed patients with advanced DLCL were treated with the regimen. Of these 30 patients, 14 (47%) were 61 years of age or more, 15 (50%) had stage IV disease, 14 (47%) presented with constitutional symptoms, and 7 (23%) had T-cell lymphoma. After the completion of therapy, 23 (77%) achieved a complete response and 6 (20%) had a partial response. The actuarial relapse-free survival at 5 years is 52% and the overall survival projected to 5 years is 47%. Toxicity was generally mild and well tolerated. Although this alternating regimen had substantial activity as front-line chemotherapy for advanced DLCL, we conclude that the observed response rate and survival do not essentially differ from those achieved with conventional regimens and further clinical trials are thus not warranted.

Original languageEnglish
Pages (from-to)93-98
Number of pages6
JournalInternational Journal of Hematology
Volume58
Issue number1-2
Publication statusPublished - 1993

Fingerprint

Mitoxantrone
Lymphoma, Large B-Cell, Diffuse
Bleomycin
Vincristine
Etoposide
Prednisolone
Doxorubicin
Cyclophosphamide
Drug Therapy
Survival Rate
Survival
T-Cell Lymphoma
Drug Combinations
Combination Drug Therapy
Clinical Trials
Recurrence
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma : A single-institutional study with a long-term follow-up. / Ohnoshi, T.; Hayashi, K.; Ueno, K.; Tada, A.; Mizuta, J.; Tagawa, S.; Matsutomo, S.; Saito, Shinya; Kawashima, K.; Yoshino, Tadashi; Kimura, I.

In: International Journal of Hematology, Vol. 58, No. 1-2, 1993, p. 93-98.

Research output: Contribution to journalArticle

Ohnoshi, T, Hayashi, K, Ueno, K, Tada, A, Mizuta, J, Tagawa, S, Matsutomo, S, Saito, S, Kawashima, K, Yoshino, T & Kimura, I 1993, 'Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma: A single-institutional study with a long-term follow-up', International Journal of Hematology, vol. 58, no. 1-2, pp. 93-98.
Ohnoshi, T. ; Hayashi, K. ; Ueno, K. ; Tada, A. ; Mizuta, J. ; Tagawa, S. ; Matsutomo, S. ; Saito, Shinya ; Kawashima, K. ; Yoshino, Tadashi ; Kimura, I. / Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma : A single-institutional study with a long-term follow-up. In: International Journal of Hematology. 1993 ; Vol. 58, No. 1-2. pp. 93-98.
@article{5ad3d775464a40029f2c9250f2f2e2d6,
title = "Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma: A single-institutional study with a long-term follow-up",
abstract = "Diffuse large-cell lymphoma (DLCL) is a neoplasm that is curable with chemotherapy in an appreciable percentage of patients. However, not all patients are cured and the best drug combination and optimal dose intensity have not yet been established. In an attempt to improve complete response rate and survival with minimal toxicity, we devised an alternating combination chemotherapy consisting of CHOP-Bleo (cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin) and POEM-Bleo (prednisolone, vincristine, etoposide, mitoxantrone, and bleomycin). Between March 1986 and October 1990, 30 newly-diagnosed patients with advanced DLCL were treated with the regimen. Of these 30 patients, 14 (47{\%}) were 61 years of age or more, 15 (50{\%}) had stage IV disease, 14 (47{\%}) presented with constitutional symptoms, and 7 (23{\%}) had T-cell lymphoma. After the completion of therapy, 23 (77{\%}) achieved a complete response and 6 (20{\%}) had a partial response. The actuarial relapse-free survival at 5 years is 52{\%} and the overall survival projected to 5 years is 47{\%}. Toxicity was generally mild and well tolerated. Although this alternating regimen had substantial activity as front-line chemotherapy for advanced DLCL, we conclude that the observed response rate and survival do not essentially differ from those achieved with conventional regimens and further clinical trials are thus not warranted.",
author = "T. Ohnoshi and K. Hayashi and K. Ueno and A. Tada and J. Mizuta and S. Tagawa and S. Matsutomo and Shinya Saito and K. Kawashima and Tadashi Yoshino and I. Kimura",
year = "1993",
language = "English",
volume = "58",
pages = "93--98",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1-2",

}

TY - JOUR

T1 - Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large- cell lymphoma

T2 - A single-institutional study with a long-term follow-up

AU - Ohnoshi, T.

AU - Hayashi, K.

AU - Ueno, K.

AU - Tada, A.

AU - Mizuta, J.

AU - Tagawa, S.

AU - Matsutomo, S.

AU - Saito, Shinya

AU - Kawashima, K.

AU - Yoshino, Tadashi

AU - Kimura, I.

PY - 1993

Y1 - 1993

N2 - Diffuse large-cell lymphoma (DLCL) is a neoplasm that is curable with chemotherapy in an appreciable percentage of patients. However, not all patients are cured and the best drug combination and optimal dose intensity have not yet been established. In an attempt to improve complete response rate and survival with minimal toxicity, we devised an alternating combination chemotherapy consisting of CHOP-Bleo (cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin) and POEM-Bleo (prednisolone, vincristine, etoposide, mitoxantrone, and bleomycin). Between March 1986 and October 1990, 30 newly-diagnosed patients with advanced DLCL were treated with the regimen. Of these 30 patients, 14 (47%) were 61 years of age or more, 15 (50%) had stage IV disease, 14 (47%) presented with constitutional symptoms, and 7 (23%) had T-cell lymphoma. After the completion of therapy, 23 (77%) achieved a complete response and 6 (20%) had a partial response. The actuarial relapse-free survival at 5 years is 52% and the overall survival projected to 5 years is 47%. Toxicity was generally mild and well tolerated. Although this alternating regimen had substantial activity as front-line chemotherapy for advanced DLCL, we conclude that the observed response rate and survival do not essentially differ from those achieved with conventional regimens and further clinical trials are thus not warranted.

AB - Diffuse large-cell lymphoma (DLCL) is a neoplasm that is curable with chemotherapy in an appreciable percentage of patients. However, not all patients are cured and the best drug combination and optimal dose intensity have not yet been established. In an attempt to improve complete response rate and survival with minimal toxicity, we devised an alternating combination chemotherapy consisting of CHOP-Bleo (cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin) and POEM-Bleo (prednisolone, vincristine, etoposide, mitoxantrone, and bleomycin). Between March 1986 and October 1990, 30 newly-diagnosed patients with advanced DLCL were treated with the regimen. Of these 30 patients, 14 (47%) were 61 years of age or more, 15 (50%) had stage IV disease, 14 (47%) presented with constitutional symptoms, and 7 (23%) had T-cell lymphoma. After the completion of therapy, 23 (77%) achieved a complete response and 6 (20%) had a partial response. The actuarial relapse-free survival at 5 years is 52% and the overall survival projected to 5 years is 47%. Toxicity was generally mild and well tolerated. Although this alternating regimen had substantial activity as front-line chemotherapy for advanced DLCL, we conclude that the observed response rate and survival do not essentially differ from those achieved with conventional regimens and further clinical trials are thus not warranted.

UR - http://www.scopus.com/inward/record.url?scp=0027427891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027427891&partnerID=8YFLogxK

M3 - Article

C2 - 7693030

AN - SCOPUS:0027427891

VL - 58

SP - 93

EP - 98

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1-2

ER -